Edition:
United States

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

124.84USD
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
$124.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
136,524
52-wk High
$179.65
52-wk Low
$105.22

Select another date:

Thu, Sep 27 2018

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

RPT-UPDATE 4-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

CORRECTED-(OFFICIAL)-UPDATE 3-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

GW Pharma wins U.S. approval for marijuana-derived epilepsy drug

June 25 An epilepsy treatment from GW Pharmaceuticals Plc on Monday secured an approval from the U.S. Food and Drug Administration, becoming the first cannabis-based drug to be approved in the country.

Select another date: